• Diagnosed as recurrence/metastatic NPC

• Histopathological diagnosis of NPC(WHO II/III)

• ECOG 0-1 point

• No treatment to r/mNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;

• No contraindications to immunotherapy and chemoradiotherapy;

• At least one lesion could receive SBRT safely;

• Subject must have a measurable target lesion based on RECIST v1.1;

• Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/ L, HGB ≥ 90g/L, PLT count ≥ 100×10E9/L;

• Adequate liver function: ALT/AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;

• Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula);

• Take effective contraceptions during and three months after treatment;

• Patients must be informed of the investigational nature of this study and give written informed consent.